ODT Odonate Therapeutics Inc.

27.97
-0.53  -2%
Previous Close 28.5
Open 28.48
Price To Book 4.72
Market Cap 900,284,095
Shares 32,187,490
Volume 119,627
Short Ratio
Av. Daily Volume 104,890
Stock charts supplied by TradingView

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial enrolment to be completed 2H 2019 with data due 2020.
Tesetaxel - CONTESSA
Metastatic breast cancer (MBC)
Phase 2 trial initiation announced March 4, 2019.
Tesetaxel - Contessa 2
Metastatic breast cancer (MBC)